PPAR α and γ agonists modulate important metabolic events and they are the targets of drugs or candidate drugs that are effective in the treatment of metabolic disorders such as T2D, atherosclerosis (Berger, Akiyama & Meinke, 2005) and obesity (Bassaganya-Riera, Guri & Hontecillas, 2011). This evidence concerns the gene PPARA and obesity due to melanocortin 4 receptor deficiency.